Smith+Nephew
Smith+Nephew is a global medical technology company with a leading presence in the Cartilage Repair and Regeneration market, known for its strong distribution channels and focus on advanced wound care and sports medicine. The company recently solidified its leadership position with the high-profile acquisition of CartiHeal, which developed the Agili-C™ implant. This novel, resorbable osteochondral scaffold is designed for cartilage regeneration in the knee and is considered a disruptive technology poised to transform patient outcomes. This acquisition supports Smith+Nephew’s strategic investment in its Sports Medicine business, aiming to provide a comprehensive portfolio of regenerative treatments. Furthermore, the company expanded its regenerative offerings by acquiring Osiris Therapeutics, Inc. in 2019, adding more advanced wound and tissue repair products, including articular cartilage replacements. By continually investing in and acquiring innovative technologies, Smith+Nephew remains at the forefront of providing solutions that preserve and repair joint function for active patients.
Latest Market Research Report on Cartilage Repair Download PDF Brochure Now
Stryker Corporation
Stryker Corporation is a major global medical technology company providing a diverse range of products and services in Orthopaedics, Medical and Surgical, and Neurotechnology. In the Cartilage Repair market, Stryker is a key player with a focus on advanced allograft technologies. The company’s offerings include ProChondrix CR, a state-of-the-art, cryopreserved osteochondral allograft. This product is designed to provide comprehensive articular cartilage restoration by incorporating live cells and other essential biological components. ProChondrix CR offers surgeons a superior solution for patients needing cartilage repair by ensuring tissue viability and excellent handling characteristics for implantation. Stryker’s commitment to innovation and strong global sales network supports the widespread adoption of its cutting-edge orthopaedic solutions, reinforcing its role in advancing the standard of care for patients with cartilage defects.
Zimmer Biomet Holdings, Inc.
Zimmer Biomet is a global leader in musculoskeletal healthcare, specializing in orthopedic reconstructive products, sports medicine, trauma, and spine. In the Cartilage Repair market, the company offers a portfolio of regenerative solutions, notably the DeNovo NT Graft. This is a novel, natural tissue-based cartilage implant used for treating articular cartilage damage. Zimmer Biomet is driving innovation not only through advanced materials but also through digital integration, exemplified by its ROSA Robotics system and the ZBEdge connected intelligence platform. These technologies are designed to enhance the precision and effectiveness of orthopedic procedures, including those for cartilage restoration. The company’s comprehensive approach, combining advanced biologics with surgical robotics and digital tools, makes it a dominant force in the market focused on improving patient mobility and clinical outcomes.
Vericel Corporation
Vericel Corporation is a fully integrated, commercial-stage biopharmaceutical company that is a recognized leader in advanced therapies for sports medicine and severe burn care. The company’s flagship product in the Cartilage Repair market is MACI (autologous cultured chondrocytes on porcine collagen membrane). MACI is an FDA-approved, autologous cellularized scaffold product used to repair symptomatic, full-thickness cartilage defects of the knee. The treatment involves culturing the patient’s own cartilage cells and then implanting them on a specialized collagen membrane, allowing the cells to regenerate the damaged tissue. Vericel’s recent product development includes MACI Arthro. This focus on pioneering cell-based regenerative medicine distinguishes Vericel as a specialist provider, offering personalized and highly effective solutions for joint preservation and restoration.
DePuy Synthes (Johnson & Johnson)
DePuy Synthes is the Orthopaedics company of Johnson & Johnson and a major player in the global Cartilage Repair market, benefiting from the extensive R&D and acquisition investments of its parent company. DePuy Synthes offers a range of devices and technologies aimed at surgical precision and bone/tissue preservation. Its contributions to cartilage repair include the COR Precision Targeting System, which is an integral part of its Osteochondral Autograft Transfer System. This system is engineered with features like “No Impact Transfer” and “Low Impact Delivery” to maximize chondrocyte viability during the procedure. The company leverages its massive infrastructure to integrate sophisticated surgical instruments and regenerative biologic solutions, ensuring that clinicians worldwide have access to high-quality, scientifically supported products for cartilage restoration and joint function preservation.
Arthrex, Inc.
Arthrex is a private, global medical device company widely known for its pioneering innovations in orthopedics, particularly in the sports medicine sector. The company has a significant focus on biologics and single-stage cartilage repair techniques. Arthrex offers the AutoCart™ surgical technique, which is a single-stage, matrix-augmented, autologous chondrocyte transplantation procedure. This approach combines a patient’s own cartilage collected using the GraftNet™ device with BioCartilage for efficient repair. Arthrex also provides solutions for orthobiologics preparation, such as the Angel® System and the Arthrex ACP® Double-Syringe System, which are used to produce customized platelet-rich plasma (PRP) formulations to enhance the healing process. Arthrex’s philosophy of “Helping Surgeons Treat Their Patients Better” drives its continuous development of comprehensive solutions for challenging joint injuries.
MEDIPOST Co., Ltd.
MEDIPOST Co., Ltd. is a leading global biotechnology company specializing in stem cell therapeutics, with a prominent position in the regenerative medicine segment of the Cartilage Repair market. The company’s key product is CARTISTEM®, which has been a groundbreaking innovation. CARTISTEM® is a cell-based therapy that utilizes human umbilical cord mesenchymal stem cells (hUC-MSCs) mixed with a biopolymer solution. This treatment is specifically indicated for the repair of full-thickness grade 3–4 articular cartilage defects of the knee. By leveraging its expertise in allogeneic stem cell technology, MEDIPOST offers a unique, off-the-shelf regenerative solution. This advanced product provides an alternative to traditional repair methods, positioning MEDIPOST as a significant driver in the adoption of next-generation, cell-based solutions for joint restoration worldwide.
Anika Therapeutics, Inc.
Anika Therapeutics, Inc. is a joint preservation and regenerative orthopedic solutions company committed to developing innovative biologic products that support cartilage repair and restoration. The company focuses on leveraging its expertise in hyaluronic acid (HA)-based products for various orthopedic applications. Anika is actively pursuing FDA approval for its pivotal product, Hyalofast, a single-stage, off-the-shelf, resorbable hyaluronic acid scaffold. Hyalofast is designed for minimally invasive treatment of knee cartilage lesions, offering a bone-preserving alternative to current surgical standards. The product has already seen clinical success and commercial availability in over 35 countries. By developing and commercializing biologically inspired solutions like Hyalofast, Anika aims to reduce pain, restore joint function, and enable patients to maintain active lifestyles without resorting to joint replacement.
Geistlich Pharma
Geistlich Pharma AG is a Swiss company with a strong focus on regenerative medicine, particularly in biomaterials for dental and orthopedic applications. In the Cartilage Repair market, Geistlich is known for its products that support the body’s natural self-healing processes. Its flagship product is Chondro-Gide®, a native bilayer collagen membrane scaffold. Chondro-Gide is specifically designed for regenerative therapies, such as the Autologous Matrix-Induced Chondrogenesis (AMIC®) technique. In the AMIC procedure, the membrane is used to cover a cartilage defect after bone marrow stimulation, guiding the migration and differentiation of cells to promote articular cartilage repair. This minimally invasive approach offers a solution that preserves and extends joint function, positioning Geistlich as a key provider of biomaterial scaffolds essential for modern cartilage regeneration surgery.
CONMED Corporation
CONMED Corporation is a global medical technology company specializing in the development and sale of surgical devices and equipment, with a strong focus on the Sports Medicine and Orthopedics sectors. CONMED is a recognized name in the Cartilage Repair market and has strategically grown its presence through the acquisition of innovative technologies, such as the sports medicine division of MedShape. Its portfolio includes a variety of advanced tools and implants used in arthroscopic surgery, which is a common procedure for cartilage reattachment and microfracture techniques. By providing comprehensive surgical solutions, from advanced instrumentation to implants and regenerative components, CONMED helps surgeons treat complex cartilage and soft-tissue injuries. The company’s commitment to creating effective, minimally invasive surgical technology reinforces its role as an essential partner in joint preservation.
Latest Market Research Report on Cartilage Repair Download PDF Brochure Now